Vanguard Group Inc. Acquires 347,074 Shares of BridgeBio Pharma, Inc. $BBIO

Vanguard Group Inc. lifted its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 2.1% during the third quarter, Holdings Channel.com reports. The firm owned 16,832,059 shares of the company’s stock after acquiring an additional 347,074 shares during the quarter. Vanguard Group Inc. owned approximately 0.09% of BridgeBio Pharma worth $874,257,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of BBIO. Assetmark Inc. grew its position in shares of BridgeBio Pharma by 57.2% in the 3rd quarter. Assetmark Inc. now owns 4,418 shares of the company’s stock valued at $229,000 after buying an additional 1,608 shares during the last quarter. Cibc World Market Inc. bought a new stake in BridgeBio Pharma in the third quarter valued at approximately $1,024,000. Stratos Wealth Partners LTD. acquired a new stake in BridgeBio Pharma during the 3rd quarter valued at approximately $350,000. Baader Bank Aktiengesellschaft bought a new position in BridgeBio Pharma during the 3rd quarter worth approximately $650,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of BridgeBio Pharma in the 3rd quarter worth approximately $407,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Pharma Price Performance

Shares of NASDAQ BBIO opened at $68.14 on Monday. The company has a 50-day moving average price of $75.52 and a 200-day moving average price of $64.22. The stock has a market capitalization of $13.13 billion, a P/E ratio of -16.30 and a beta of 1.13. BridgeBio Pharma, Inc. has a 1 year low of $28.33 and a 1 year high of $84.94.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BBIO shares. Raymond James Financial set a $89.00 target price on shares of BridgeBio Pharma and gave the company an “outperform” rating in a report on Thursday, February 12th. Barclays assumed coverage on BridgeBio Pharma in a research report on Wednesday, January 28th. They set an “overweight” rating on the stock. Evercore reiterated an “outperform” rating on shares of BridgeBio Pharma in a report on Monday, October 27th. Sanford C. Bernstein started coverage on shares of BridgeBio Pharma in a research report on Thursday, December 11th. They set an “outperform” rating and a $94.00 price objective for the company. Finally, TD Cowen reiterated a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, January 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $82.05.

Insider Buying and Selling

In other BridgeBio Pharma news, CAO Maricel Apuli sold 510 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.31, for a total transaction of $37,898.10. Following the transaction, the chief accounting officer directly owned 123,945 shares in the company, valued at approximately $9,210,352.95. This trade represents a 0.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Thomas Trimarchi sold 13,600 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the completion of the sale, the chief financial officer owned 336,585 shares of the company’s stock, valued at approximately $25,149,631.20. The trade was a 3.88% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 176,121 shares of company stock valued at $13,009,631. Company insiders own 18.20% of the company’s stock.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL 3 results improve the commercial and regulatory outlook for BridgeBio’s achondroplasia program — a fundamental driver for longer‑term upside. PROPEL 3 Results
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and boosted its price target to $100 while maintaining a Buy — analyst upgrades can support buying interest and help re‑rate shares if fundamentals continue to improve. HC Wainwright PT Raise
• Positive Sentiment: Broad analyst coverage remains constructive (multiple Buy/Overweight ratings and higher targets), which can amplify rallies following positive clinical/financial news. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results and host a Feb. 24 conference call — this is the next near‑term catalyst that could drive volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to new hires (~76,701 shares aggregate) — modest ongoing share‑based comp that could be a small dilution factor to monitor. Inducement Grants
• Neutral Sentiment: Oppenheimer reported a small new 13F position (~7,845 shares) — modest institutional interest but not yet material to the register. Oppenheimer 13F
• Neutral Sentiment: Short‑interest reporting for Feb. 19 shows anomalous/zero values in the feed (likely a data/reporting glitch) — no clear evidence of a meaningful short squeeze or build from this item alone.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal W. Scott sold 10,000 shares and senior officers (CFO and CAO) also disclosed sales (CFO ~13,600 shares; CAO 510 shares) — concentrated insider disposals are weighing on near‑term sentiment. Insider Trades
• Negative Sentiment: Ongoing pattern of executive liquidity events highlighted in reporting — repeated insider selling can keep downward pressure on the stock until insiders demonstrate renewed accumulation. Insider/Sentiment Summary

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.